Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


The add-on effect of dengzhan shengmai capsules on secondary prevention of ischemic stroke: A multicentre, randomised, placebo-controlled clinical trial.

Cai Y, Zhang X, Huang Y, Wang L, Sun J, Liang W, Ou A, Yu B, Guo J, Zhao M, Ni X, Chen S.

Complement Ther Med. 2019 Oct;46:189-194. doi: 10.1016/j.ctim.2019.08.015. Epub 2019 Aug 24.


Chinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: A systematic review and meta-analysis of randomized clinical trials.

Yang XY, Wang LQ, Li JG, Liang N, Wang Y, Liu JP.

Complement Ther Med. 2018 Feb;36:82-89. doi: 10.1016/j.ctim.2017.12.004. Epub 2017 Dec 9. Review.


Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats.

Chen X, Zhao Z, Chen Y, Gou X, Zhou Z, Zhong G, Cai Y, Huang M, Jin J.

J Ethnopharmacol. 2016 Nov 4;192:362-369. doi: 10.1016/j.jep.2016.07.066. Epub 2016 Jul 25.


[Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke].

Wei X, Ye X, Xie Y, Zou Y, Zhao X, Han J, Wang X, Ma Y, Bi Q, Xie Q, Zhao J, Cao X, Chen H, Wang S, Yan R, Han Z, Yi D, Wang Y.

Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2789-92. Chinese.


Chinese herbal medicine Dengzhan Xixin injection for acute ischemic stroke: A systematic review and meta-analysis of randomised controlled trials.

Li JG, Wang LQ, Yang XY, Chen Z, Lai LYW, Xu H, Liu JP.

Complement Ther Med. 2017 Oct;34:74-85. doi: 10.1016/j.ctim.2017.08.004. Epub 2017 Aug 11. Review.


Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT.

Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Ciccone A, Collins R, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Karlinski M, Krishnan K, Laska AC, Law ZK, Ovesen C, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Peters N, Scutt P, Thanabalan J, Werring D, Whynes D, Woodhouse L, Bath PM.

Health Technol Assess. 2019 Jul;23(35):1-48. doi: 10.3310/hta23350.


Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7. Lancet Diabetes Endocrinol. 2019 May;7(5):e5.


Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators.

N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 26.


Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.


Meta-analysis of traditional Chinese patent medicine for ischemic stroke.

Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, Fang Y.

Stroke. 2007 Jun;38(6):1973-9. Epub 2007 Apr 26.


Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G; ARRIVE Executive Committee.

Lancet. 2018 Sep 22;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26.


Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial.

Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, Shahbegi S, Pakdaman H, Tabasi M, Tabatabae AL, Nourian A.

Stroke Res Treat. 2011;2011:721613. doi: 10.4061/2011/721613. Epub 2011 Jun 21.


Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC.

Cochrane Database Syst Rev. 2017 Jan 17;1:CD003146. doi: 10.1002/14651858.CD003146.pub3. Review.


Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).

Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Špinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MS.

Circulation. 2016 Sep 20;134(12):861-71. doi: 10.1161/CIRCULATIONAHA.116.024637. Epub 2016 Aug 30.


Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial.

Ford GA, Bhakta BB, Cozens A, Hartley S, Holloway I, Meads D, Pearn J, Ruddock S, Sackley CM, Saloniki EC, Santorelli G, Walker MF, Farrin AJ.

Lancet Neurol. 2019 Jun;18(6):530-538. doi: 10.1016/S1474-4422(19)30147-4.


Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.

Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA.

Circulation. 2015 Mar 24;131(12):1047-53. doi: 10.1161/CIRCULATIONAHA.114.013774. Epub 2015 Feb 13.

Supplemental Content

Support Center